Granules India Limited
Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.
What Granules files
- Others42
- Investor Meet36
- Updates34
- Important12
- Board Meeting12
- PPTs4
Granules India Promoter Dr. Krishna Prasad Chigurupati sold 1.72 crore equity shares via block deal and open market to institutional investors. Proceeds fund the preferential issue's second tranche and accelerate strategic growth initiatives. Promoter shareholding dropped from 38.02% to 31.08%, boosting institutional participation while driving aggressive expansion plans.
Granules India Limited has announced that its management will meet with a group of analysts, investors, and funds in Hyderabad to discuss general business updates and operations, ensuring no unpublished price-sensitive information will be shared during the interaction.
Granules India Limited has informed the Exchange about change in Management
Granules India Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 06, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report.
Granules India Limited reported a strong Q1 FY27, with revenue up 22% YoY to INR1,477 Cr. EBITDA grew 37% to INR338.9 Cr (22.9% margin), and PAT surged 60% to INR180 Cr. Gross margin remained healthy at 65.6%. Net debt significantly reduced to INR101.2 Cr, and operating cash generation was robust...